Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

ConditionMetastatic Prostate Cancer

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexMale

Age18+

SponsorJanssen Research & Development, LLC

About this trial

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

JNJ-101556143 Formulation 1
JNJ-101556143 Formulation 2
JNJ-101556143 Formulation 3

Treatment groups

190 Participants

are divided into 7 treatment groups

Treatment groups

See each treatment group below.

Locations18

Select a site below to view it on the map.

United Kingdom

United States

Colorado

Connecticut

Florida

Louisiana

Massachusetts

Michigan

Nebraska

New York

North Carolina

South Carolina

Tennessee

Texas

Virginia

Sponsors and collaborators

Janssen Research & Development, LLC

Lead sponsor

Source ClinicalTrials.gov